HC Wainwright restated their buy rating on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $25.00 price objective on the stock. HC Wainwright also issued estimates for Longboard Pharmaceuticals’ Q1 2023 earnings at ($0.55) EPS, Q2 2023 earnings at ($0.56) EPS, Q3 2023 earnings at ($0.39) EPS, Q4 2023 earnings at ($0.40) EPS, FY2023 earnings at ($1.89) EPS, FY2024 earnings at ($1.13) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.61) EPS and FY2027 earnings at ($0.29) EPS.
A number of other research firms have also commented on LBPH. Wedbush reissued an outperform rating on shares of Longboard Pharmaceuticals in a report on Friday, March 3rd. Citigroup reduced their target price on Longboard Pharmaceuticals from $24.00 to $17.00 and set a buy rating for the company in a report on Sunday, March 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of Buy and a consensus target price of $19.33.
Longboard Pharmaceuticals Trading Down 10.5 %
Longboard Pharmaceuticals stock opened at $3.84 on Wednesday. The firm has a market cap of $88.20 million, a price-to-earnings ratio of -1.49 and a beta of 1.17. The stock has a fifty day simple moving average of $5.03 and a two-hundred day simple moving average of $4.39. Longboard Pharmaceuticals has a 12 month low of $2.70 and a 12 month high of $6.47.
Institutional Trading of Longboard Pharmaceuticals
Longboard Pharmaceuticals Company Profile
Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
- Get a free copy of the StockNews.com research report on Longboard Pharmaceuticals (LBPH)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Longboard Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longboard Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.